The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions.
The induction of antitumor immune responses by dendritic cell (DC)/tumor cell fusions can be modulated by their activation status. Our recent work reveals that the combination of Toll-like receptor 2 (TLR2) and TLR4 agonists promotes the immunogenicity of DC/tumor cell fusions, allowing them to overcome the immunosuppressive effects of transforming growth factor β1.
Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan ; Institute of Clinical Medicine and Research; The Jikei University School of Medicine; Tokyo, Japan ; Department of Oncology; The Jikei University School of Medicine; Tokyo, Japan.
Shigeo
S
Koido
Sadamu
S
Homma
Masato
M
Okamoto
Yoshihisa
Y
Namiki
Kazuki
K
Takakura
Kan
K
Uchiyama
Mikio
M
Kajihara
Toshifumi
T
Ohkusa
Jianlin
J
Gong
Hisao
H
Tajiri
Toll-like receptor; cytotoxic T lymphocyte; dendritic cell; fusion cell; whole tumor cell